Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Intercept Pharmaceut (ICPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,678,909
  • Shares Outstanding, K 24,830
  • Annual Sales, $ 24,950 K
  • Annual Income, $ -412,830 K
  • 36-Month Beta -2.00
  • Price/Sales 106.67
  • Price/Cash Flow 0.00
  • Price/Book 8.44

Price Performance

See More
Period Period Low Period High Performance
1-Month
104.86 +4.22%
on 04/18/17
124.25 -12.05%
on 03/29/17
-7.45 (-6.38%)
since 03/24/17
3-Month
104.10 +4.98%
on 01/31/17
135.25 -19.20%
on 02/16/17
+3.88 (+3.68%)
since 01/24/17
52-Week
96.63 +13.09%
on 11/04/16
177.93 -38.58%
on 08/01/16
-48.46 (-30.72%)
since 04/22/16

Most Recent Stories

More News
Amgen (AMGN) to Report Q1 Earnings: Will it Beat Again?

We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports first-quarter 2017 results on Apr 26 after the market closes.

CLDX : 3.20 (+0.31%)
GILD : 66.22 (+0.44%)
ICPT : 110.44 (+2.36%)
AMGN : 162.61 (+1.37%)
Alexion (ALXN) Q1 Earnings: Can the Stock Pull a Surprise?

Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report first quarter 2017 results on Apr 27, before the opening bell.

GILD : 66.22 (+0.44%)
ICPT : 110.44 (+2.36%)
AMGN : 162.61 (+1.37%)
ALXN : 119.21 (+2.05%)
Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?

Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.

NVS : 74.30 (+1.23%)
GILD : 66.22 (+0.44%)
ICPT : 110.44 (+2.36%)
AMGN : 162.61 (+1.37%)
Allergan (AGN) Collaborates with Novartis to Treat NASH

Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic...

CNAT : 7.71 (+2.25%)
AGN : 238.13 (+0.75%)
NVS : 74.30 (+1.23%)
ICPT : 110.44 (+2.36%)
How These Biotech Stocks are Faring? -- FibroGen, Bellicum Pharma, Intercept Pharma, and Cellect Biotechnology

On Thursday, April 13, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Nine out of nine sectors ended Thursday's trading session in bearish...

FGEN : 26.40 (+1.34%)
BLCM : 13.56 (+1.04%)
ICPT : 110.44 (+2.36%)
APOP : 8.03 (+1.13%)
Intercept to Present at Upcoming Conference

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced...

ICPT : 110.44 (+2.36%)
Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales and Northern Ireland

Upcoming AWS Coverage on Exelixis Post-Earnings Results

EXEL : 21.44 (+2.19%)
ICPT : 110.44 (+2.36%)
NICE Recommends Ocaliva(R) (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland

First new medication for primary biliary cholangitis in nearly 20 years

ICPT : 110.44 (+2.36%)
NICE Recommends Ocaliva(R) (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland

First new medication for primary biliary cholangitis in nearly 20 years

ICPT : 110.44 (+2.36%)
Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat

Intercept Pharmaceuticals, Inc. (ICPT) posted a loss of $4.84 per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of a loss of $3.58.

CELG : 123.27 (+0.83%)
ICPT : 110.44 (+2.36%)
SNSS : 3.67 (-1.08%)
GSK : 41.10 (+0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Intercept Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease. The company's lead product candidate, obeticholic acid, or OCA, is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR)....

See More

Support & Resistance

2nd Resistance Point 109.54
1st Resistance Point 108.71
Last Price 110.44
1st Support Level 106.78
2nd Support Level 105.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.